<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02829723</url>
  </required_header>
  <id_info>
    <org_study_id>CBLZ945X2101</org_study_id>
    <secondary_id>2015-005806-12</secondary_id>
    <nct_id>NCT02829723</nct_id>
  </id_info>
  <brief_title>A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors</brief_title>
  <official_title>A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human (FIH) study of BLZ945 given as a single agent or in
      combination with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK),
      pharmacodynamics, and anti-tumor activity of BLZ945, administered orally, as a single agent
      or in combination with PDR001, administered intravenously (i.v.) in adult patients with
      advanced solid tumors.

      Dose escalation will be guided by a Bayesian logistic regression model with overdose control.
      Once MTD/ RP2D is declared, glioblastoma patients will be enrolled in the phase II part to
      further assess the preliminary anti-tumor activity of BLZ945 as single agent and in
      combination with PDR001.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 21, 2016</start_date>
  <completion_date type="Anticipated">March 19, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Dose limiting toxicities (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Adverse Events (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose interruptions (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose reductions (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Dose intensity (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>To identify the Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival probability (PFSP) at 6 months (Phase II)</measure>
    <time_frame>6 months</time_frame>
    <description>Percentage of participants with Progression Free Survival (PFS) at 6 months per RANO criteria</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CD163 (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>On treatment versus baseline comparison of pharmacodynamics markers expressions by immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD8 (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>On treatment versus baseline comparison of pharmacodynamics markers expressions by immunohistochemistry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation is based on RECISTv1.1 or irRC or RANO or iRANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation is based on RECISTv1.1 or irRC or RANO or iRANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR) (Phase I)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation is based on RECISTv1.1 or RANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS (Phase II)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation is based on iRANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BOR (Phase II)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation is based on RANO or iRANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration Of Response (DOR) (Phase II)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation is based on RANO or iRANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR (Phase II)</measure>
    <time_frame>5 years</time_frame>
    <description>Evaluation is based on RANO or iRANO</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) (Phase II)</measure>
    <time_frame>6 years</time_frame>
    <description>every 12 weeks until end of study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs (Phase II)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of SAEs (Phase II)</measure>
    <time_frame>5 years</time_frame>
    <description>Assessment to be completed at least every 28 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) Area Under the Curve (AUC) (BLZ945 single agent)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK AUC (BLZ945 + PDR001)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Time of maximum concentration observed (Tmax) (BLZ945 single agent)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Tmax (BLZ945 + PDR001)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK peak serum concentration (Cmax) (BLZ945 + PDR001)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK Cmax (BLZ945 single agent)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of anti-PDR001 antibodies (BLZ945 + PDR001)</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <arm_group>
    <arm_group_label>BLZ945 single agent</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>BLZ945 + PDR001</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BLZ945</intervention_name>
    <arm_group_label>BLZ945 + PDR001</arm_group_label>
    <arm_group_label>BLZ945 single agent</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <arm_group_label>BLZ945 + PDR001</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Phase I: Patients with advanced/metastatic solid tumors, with measurable or
             unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          2. Phase I: Patients with a site of disease amenable to biopsy, and willing to undergo a
             new tumor biopsy at screening, and during treatment.

          3. Phase II: Patients with advanced/metastatic/recurrent isocitrate dehydrogenase (IDH)
             wild-type glioblastoma, with at least one measurable lesion as determined by RANO

        Other protocol defined inclusion criteria may apply

        Exclusion Criteria:

          1. History of severe hypersensitivity reactions to monoclonal antibodies.

          2. Impaired cardiac function or clinically significant cardiac disease.

          3. Active autoimmune disease or a documented history of autoimmune disease.

          4. Systemic steroid therapy or any immunosuppressive therapy

          5. Use of any vaccines against infectious diseases within 4 weeks of initiation of study
             treatment.

          6. Patient receiving treatment with medications that either strong inducers or inhibitors
             of CYP2C8 or CYP3A4/5, or patients receiving medication that prohibits proton pump
             inhibitors and that cannot be discontinued at least 1 week prior to start of treatment
             and for the duration of the study.

        Other protocol defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>Novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeremy Stewart</last_name>
      <phone>615-289-9227</phone>
      <email>jeremy.stewart@scresearch.net</email>
    </contact>
    <investigator>
      <last_name>Todd M. Bauer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lacey McQuinn</last_name>
      <phone>713-563-9033</phone>
      <email>lmcquinn@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Aung Naing</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathleen Rodriguez</last_name>
      <phone>210-450-3838</phone>
      <email>rodriguezk3@uthscsa.edu</email>
    </contact>
    <investigator>
      <last_name>John Sarantopoulos</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tel Aviv</city>
        <zip>6423906</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rozzano</city>
        <state>MI</state>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nagoya</city>
        <state>Aichi</state>
        <zip>466 8560</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koto ku</city>
        <state>Tokyo</state>
        <zip>135 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hospitalet de LLobregat</city>
        <state>Catalunya</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>July 8, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I/II</keyword>
  <keyword>BLZ945</keyword>
  <keyword>PDR001</keyword>
  <keyword>CSF-1R</keyword>
  <keyword>PD-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

